Published in Women's Health Weekly, August 24th, 2000
The company expects, within 45-60 days, to report results of this feasibility and safety trial to the U.S. Food and Drug Administration and apply for permission to begin the final and pivotal Phase II multi-center trials necessary to obtain approval for commercialization.
Celsion's approach differs significantly from current breast cancer therapies. It is a minimally invasive outpatient procedure. The patient undergoes a single focused heat treatment using tumor-targeting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly